We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson’s Tiger Management. Robertson put together a formidable team of young traders – called the Tiger Cubs – in the 1990s, and most founded their own hedge funds after exit. Some other noteworthy names include Robert Citrone, Chase Coleman, and John Griffin. Halvorsen is the wealthiest Tiger Cub. Forbes Magazine ranks him at position 382 in the Richest People in the World in 2025 list with an $8 billion net worth.
The Norwegian billionaire founded Viking Global Investors LP in 1999 with former Tiger Management employees Brian Olson and David Ott. Halvorsen was an equity trader at Tiger Management, and the strategies and principles he used there form a core foundation of Viking Global’s approach. The fund conducts extensive due diligence on individual companies to identify undervalued (long) or overvalued (short) stocks. In short, Halvorsen generates much of his returns using the classic long/short equity strategy.
READ ALSO: Billionaire Steve Cohen’s 10 Large-Cap Stock Picks With Huge Upside Potential and Billionaire Prem Watsa’s 10 Stock Picks With Highest Potential.
But most importantly, Halvorsen is popular for his bold bets. And on many occasions, these bets have returned massive gains. For instance, in the first full year of Viking Global’s existence, the fund returned 89% after fees. More recently, in Q4 2024, the billionaire made three banks his top holdings. As of April 2025, the banking sector (within Halvorsen’s portfolio) is performing well and is the only sector that is up year-to-date.
If anything, Halvorsen’s approach teaches that playing the long game might be a great strategy for favorable gains. Many of the stocks in Viking Global’s portfolio have been there for many years, often bought when they weren’t so popular. In that light, it is prudent to examine what stocks the billionaire is invested in, especially those with considerable upside potential.
Our Methodology
We reviewed Viking Global’s Q4 2024 SEC 13F filings to compile this list. Out of the 86 holdings, we focused only on shares in companies and excluded interests in ETFs and options. From the result, we selected the top 10 stocks with the highest upside potential (as of April 28). Additionally, we have mentioned the hedge fund sentiment around each stock as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A team of scientists in white lab coats reviewing lab results in a research facility.
BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Upside Potential as of April 28: 56.39%
Viking Global’s Stake Value: $689,319,993
Number of Hedge Fund Holders: 48
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company that develops treatments for genetic diseases and cancers. Its products include therapies targeting rare conditions and innovative cancer treatments. The company operates mainly in the US, Japan, and Europe but has global end markets.
In Q4 2024, BridgeBio’s (NASDAQ:BBIO) revenue was $5.9 million, a substantial growth from $1.7 million in the same period in fiscal year 2023. Full-year revenue reached $221.9 million, many multiples more than the $9.3 million posted in 2023. According to the company, this growth was driven by the commercial launch of Attruby and licensing agreements. The company ended the fourth quarter with $681.2 million in cash and cash equivalents and expects to receive $105 million in regulatory milestones in the first half of 2025.
BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) flagship product, Attruby, saw 1,028 prescriptions by 516 prescribers by February; it earned EU approval (BEYONTTRA) with a $75M milestone and Japanese approval in March 2025, triggering a $30M milestone. On April 15, 2025, H.C. Wainwright analyst Raghuram Selvaraju raised BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) price target to $53 from $49, maintaining a Buy rating on the shares.
Overall, BBIO ranks 3rd on our list of billionaire Andreas Halvorsen’s stock picks with huge upside potential. While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BBIO but that trades at less than 5 times its earnings check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
